The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Idiopathic pulmonary fibrosis: Current and future treatment
Open accessAbstract
Objectives: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and architecture is destroyed, compliance is lost, and gas exchange is compromised in this debilitating condition that leads inexorably to respiratory failure and death within 3–5 years of diagnosis. This review discusses treatment approaches to IPF in current use and those that appear promising for future development. Data Source: The data were obtained from the Randomized Controlled Trials and scientific studies published in English literature. We used search terms related to IPF, antifibrotic treatment, lung transplant, and management. Results: Etiopathogenesis of IPF is not fully understood, and treatment options are limited. Pathological features of IPF include extracellular matrix remodeling, fibroblast activation and proliferation, immune dysregulation, cell senescence, and presence of aberrant basaloid cells. The mainstay therapies are the oral antifibrotic drugs pirfenidone and nintedanib, which can improve quality of life, attenuate symptoms, and slow disease progression. Unilateral or bilateral lung transplantation is the only treatment for IPF shown to increase life expectancy. Conclusion: Clearly, there is an unmet need for accelerated research into IPF mechanisms so that progress can be made in therapeutics toward the goals of increasing life expectancy, alleviating symptoms, and improving well‐being.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“INPULSIS phase 3 trials I and II showed a significant decrease in the rate of FVC deterioration in IPF patients although the death rate remained the same.(66) The side effects, primarily diarrhea and nausea, are manageable with medication, but hepatotoxicity may occur in rare cases and the drug is not recommended for…”
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020 · cited 1×
“Lung architecture is disrupted leading to impaired gas exchange (Figure 1).(6) IPF is most often imaged by computer tomography (CT), but a role for magnetic resonance imaging is emerging.”
BackgroundPrednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Adams, T. S., Schupp, J. C., Poli, S., Ayaub, E. A., Neumark, N., Ahangari, F., Chu, S. G., Raby, B. A., DeIuliis, G., Januszyk, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1983 · Cited by 1,420
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V., & Waldron, J. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.1.9001319 · Cited by 767
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Snell, G. I., Yusen, R. D., Weill, D., Strueber, M., Garrity, E., Reed, A., Pelaez, A., Whelan, T. P., Perch, M., Bag, R., et al. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.021 · Cited by 703
Rossano, J. W., Cherikh, W. S., Chambers, D. C., Goldfarb, S., Hayes, D., Khush, K. K., Kucheryavaya, A. Y., Toll, A. E., Levvey, B. J., Meiser, B., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.018 · Cited by 636
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Lipson, K. E., Wong, C., Teng, Y., & Spong, S. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s24 · Cited by 575
Role of Epithelial Cells in Idiopathic Pulmonary Fibrosis: From Innocent Targets to Serial Killers
Selman, M., & Pardo, A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-003tk · Cited by 529
Yusen, R. D., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Dipchand, A. I., Dobbels, F., Goldfarb, S. B., Levvey, B. J., Lund, L. H., Meiser, B., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.08.004 · Cited by 523
Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis
Moeller, A., Gilpin, S. E., Ask, K., Cox, G., Cook, D., Gauldie, J., Margetts, P. J., Farkas, L., Dobranowski, J., Boylan, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1534oc · Cited by 513
Chambers, D. C., Cherikh, W. S., Goldfarb, S. B., Hayes, D., Kucheryavaya, A. Y., Toll, A. E., Khush, K. K., Levvey, B. J., Meiser, B., Rossano, J. W., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.020 · Cited by 498
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
Olson, A. L., Swigris, J. J., Lezotte, D. C., Norris, J. M., Wilson, C. G., & Brown, K. K. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-044oc · Cited by 435
Interobserver Variability in the CT Assessment of Honeycombing in the Lungs
Watadani, T., Sakai, F., Johkoh, T., Noma, S., Akira, M., Fujimoto, K., Bankier, A. A., Lee, K. S., Müller, N. L., Song, J.-W., et al. (2013) · Radiology · doi:10.1148/radiol.12112516 · Cited by 411
TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
Murray, L. A., Chen, Q., Kramer, M. S., Hesson, D. P., Argentieri, R. L., Peng, X., Gulati, M., Homer, R. J., Russell, T., van Rooijen, N., et al. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.013 · Cited by 362 · cited 1×
“113–115 Serum PTX2 levels are significantly lower in IPF patients than in healthy controls.(114) High local levels of PTX2 can delay wound healing via inhibition of fibrocytes and macrophages, which limits scarring and fibrosis around wounds.”
BackgroundIPF lung fibroblasts have a senescent phenotype
Álvarez, D., Cárdenes, N., Sellarés, J., Bueno, M., Corey, C., Hanumanthu, V. S., Peng, Y., D’Cunha, H., Sembrat, J., Nouraie, M., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00220.2017 · Cited by 342
Lama, V. N., Smith, L., Badri, L., Flint, A., Andrei, A.-C., Murray, S., Wang, Z., Liao, H., Toews, G. B., Krebsbach, P. H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29713 · Cited by 318
Lung transplantation for idiopathic pulmonary fibrosis
George, P. M., Patterson, C. M., Reed, A. K., & Thillai, M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30502-2 · Cited by 297
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30262-0 · Cited by 293
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis
Oikonomou, N., Mouratis, M.-A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D., & Aidinis, V. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0004oc · Cited by 250
Glassberg, M. K., Minkiewicz, J., Toonkel, R. L., Simonet, E. S., Rubio, G. A., DiFede, D., Shafazand, S., Khan, A., Pujol, M. V., LaRussa, V. F., et al. (2017) · Chest · doi:10.1016/j.chest.2016.10.061 · Cited by 249
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vasakova, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2018) · JAMA · doi:10.1001/jama.2018.6129 · Cited by 227
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
Hirani, N., MacKinnon, A. C., Nicol, L., Ford, P., Schambye, H., Pedersen, A., Nilsson, U. J., Leffler, H., Sethi, T., Tantawi, S., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02559-2020 · Cited by 220
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey
Cosgrove, G. P., Bianchi, P., Danese, S., & Lederer, D. J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0560-x · Cited by 208
Serum Amyloid P Inhibits Fibrosis Through FcγR-Dependent Monocyte-Macrophage Regulation in Vivo
Castaño, A. P., Lin, S.-L., Surowy, T., Nowlin, B. T., Turlapati, S. A., Patel, T., Singh, A., Li, S., Lupher, M. L., & Duffield, J. S. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000111 · Cited by 206
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Ley, B., Swigris, J., Day, B.-M., Stauffer, J. L., Raimundo, K., Chou, W., & Collard, H. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0091oc · Cited by 206
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis: A Randomized Trial
Horton, M. R., Santopietro, V., Mathew, L., Horton, K. M., Polito, A. J., Liu, M. C., Danoff, S. K., & Lechtzin, N. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-6-201209180-00003 · Cited by 204
Lung transplantation in telomerase mutation carriers with pulmonary fibrosis
Silhan, L. L., Shah, P. D., Chambers, D. C., Snyder, L. D., Riise, G. C., Wagner, C. L., Hellström-Lindberg, E., Orens, J. B., Mewton, J. F., Danoff, S. K., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00060014 · Cited by 192
Quantitative Computed Tomography Imaging of Interstitial Lung Diseases
Bartholmai, B. J., Raghunath, S., Karwoski, R. A., Moua, T., Rajagopalan, S., Maldonado, F., Decker, P. A., & Robb, R. A. (2013) · Journal of Thoracic Imaging · doi:10.1097/rti.0b013e3182a21969 · Cited by 179
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis
Newton, C. A., Zhang, D., Oldham, J. M., Kozlitina, J., Ma, S.-F., Martinez, F. J., Raghu, G., Noth, I., & Garcia, C. K. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1646oc · Cited by 173
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A. L., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 162
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01487-0 · Cited by 161
Serum Amyloid P Component Binds to Fcγ Receptors and Opsonizes Particles for Phagocytosis
Bharadwaj, D., Mold, C., Markham, E., & Du Clos, T. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6735 · Cited by 158
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0037 · Cited by 158
Desroy, N., Housseman, C., Bock, X., Joncour, A., Bienvenu, N., Cherel, L., Labeguere, V., Rondet, E., Peixoto, C., Grassot, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00032 · Cited by 148
Mesenchymal Stem Cells and Idiopathic Pulmonary Fibrosis. Potential for Clinical Testing
Toonkel, R. L., Hare, J. M., Matthay, M. A., & Glassberg, M. K. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1204pp · Cited by 147
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
Sprunger, D. B., Olson, A. L., Huie, T. J., Pérez, E. R. F., Fischer, A., Solomon, J., Brown, K. M., & Swigris, J. J. (2011) · European Respiratory Journal · doi:10.1183/09031936.00041411 · Cited by 146
Autotaxin in Pathophysiology and Pulmonary Fibrosis
Ninou, I., Magkrioti, C., & Aidinis, V. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00180 · Cited by 137
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 137
Valenzi, E., Tabib, T., Papazoglou, A., Sembrat, J., Bittar, H. E. T., Rojas, M. M., & Lafyatis, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.595811 · Cited by 133
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
The Idiopathic Pulmonary Fibrosis Cell Atlas
Neumark, N., Cosme, C., Rose, K.-A., & Kaminski, N. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00451.2020 · Cited by 127
Optimizing quality of life in patients with idiopathic pulmonary fibrosis
van Manen, M. J. G., Geelhoed, J. J. M., Tak, N. C., & Wijsenbeek, M. S. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816686743 · Cited by 124
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Martínez, F. J., Chisholm, A., Collard, H. R., Flaherty, K. R., Myers, J. L., Raghu, G., Walsh, S. L. F., White, E. S., & Richeldi, L. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30325-3 · Cited by 121
Clinical outcomes of lung transplant recipients with telomerase mutations
Tokman, S., Singer, J. P., Devine, M., Westall, G. P., Aubert, J., Tamm, M., Snell, G. I., Lee, J. S., Goldberg, H. J., Kukreja, J., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.002 · Cited by 107
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R. A., Durham, K., Gulati, M., Huang, H. J., Roman, J., Newby, L. K., Flaherty, K. R., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1190-z · Cited by 106
Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
Fisher, J. H., Kolb, M. R. J., Algamdi, M., Morisset, J., Johannson, K. A., Shapera, S., Wilcox, P., To, T. M., Sadatsafavi, M., Manganas, H., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0986-4 · Cited by 106
Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice
Tabata, C., Tabata, R., Kadokawa, Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T., & Kubo, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.708 · Cited by 104
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30172-9 · Cited by 103
Maher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Kondoh, Y., Taniguchi, H., Yokoi, T., Nishiyama, O., Ohishi, T., Kato, T., Suzuki, K., & Suzuki, R. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00071004 · Cited by 102
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, M. S., Trehu, E., Bartholmai, B. J., & Burggraaf, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00850-2015 · Cited by 102
Picozzi, V. J., Alseidi, A. A., Winter, J., Pishvaian, M. J., Mody, K., Glaspy, J. A., Larson, T. G., Matrana, M. R., Carney, M., Porter, S., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000668 · Cited by 102
Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202007-901oc · Cited by 101
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
Wuyts, W. A., Wijsenbeek, M. S., Bondue, B., Bouros, D. E., Bresser, P., Cordeiro, C. R., Hilberg, O., Magnusson, J. M., Manali, E. D., Morais, A., et al. (2019) · Respiration · doi:10.1159/000504763 · Cited by 101
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis
Dillingh, M. R., van den Blink, B., Moerland, M., van Dongen, M. G. J., Levi, M. M., KleinJan, A., Wijsenbeek, M. S., Lupher, M., Harper, D. M., Getsy, J. A., et al. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.01.008 · Cited by 100
Serum amyloid P: a systemic regulator of the innate immune response
Cox, N., Pilling, D., & Gomer, R. H. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.1mr0114-068r · Cited by 100
Auscultation of Velcro Crackles is Associated With Usual Interstitial Pneumonia
Sellarés, J., Hernández‐González, F., Lucena, C. M., Paradela, M., Brito‐Zerón, P., Prieto‐González, S., Benegas, M., Cuerpo, S., Espinosa, G., Ramírez, J., et al. (2016) · Medicine · doi:10.1097/md.0000000000002573 · Cited by 99
Pentraxins: Multifunctional proteins at the interface of innate immunity and inflammation
Deban, L., Bottazzi, B., Garlanda, C., de la Torre, Y. M., & Mantovani, A. (2009) · Biofactors · doi:10.1002/biof.21 · Cited by 96
Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.581828 · Cited by 94
Human antigen R contributes to hepatic stellate cell activation and liver fibrosis
Woodhoo, A., Iruarrizaga‐Lejarreta, M., Beraza, N., García‐Rodríguez, J. L., Embade, N., Fernández‐Ramos, D., Martínez-López, N., Juan, V. G., Arteta, B., Caballería, J., et al. (2012) · Hepatology · doi:10.1002/hep.25828 · Cited by 92
Diabetes Is a Major Risk Factor for Mortality After Lung Transplantation
Hackman, K. L., Bailey, M., Snell, G. I., & Bach, L. A. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12561 · Cited by 90
Treatment of Interstitial Lung Disease Associated Cough
Birring, S. S., Kavanagh, J. E., Irwin, R. S., Keogh, K. A., Lim, K. G., Ryu, J. H., Adams, T. M., Altman, K. W., Azoulay, É., Barker, A. F., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.06.038 · Cited by 87
PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
Duffield, J. S., & Lupher, M. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.5.1444206 · Cited by 84
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Tzouvelekis, A., Toonkel, R. L., Karampitsakos, Τ., Medapalli, K., Ninou, I., Aidinis, V., Bouros, D. E., & Glassberg, M. K. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00142 · Cited by 81
Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment
Ghumman, M., Dhamecha, D. L., Gonsalves, A., Fortier, L., Sorkhdini, P., Zhou, Y., & Menon, J. U. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.017 · Cited by 81
Persistent Lung Inflammation and Fibrosis in Serum Amyloid P Component (Apcs-/-) Knockout Mice
Pilling, D., & Gomer, R. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093730 · Cited by 80
Targeting exosome‐associated human antigen R attenuates fibrosis and inflammation in diabetic heart
Govindappa, P. K., Patil, M., Garikipati, V. N. S., Verma, S. K., Saheera, S., Narasimhan, G., Zhu, W., Kishore, R., Zhang, J. J., & Krishnamurthy, P. (2019) · The FASEB Journal · doi:10.1096/fj.201901995r · Cited by 80
Justet, A., Klay, D., Porcher, R., Cottin, V., Ahmad, K., Molina‐Molina, M., Nunès, H., Reynaud‐Gaubert, M., Naccache, J. M., Manali, E. D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.03198-2020 · Cited by 80
Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., & Voltolini, L. (2018) · Pulmonology · doi:10.1016/j.pulmoe.2018.06.003 · Cited by 78
Lung transplantation in idiopathic pulmonary fibrosis
Kumar, A., Kapnadak, S. G., Girgis, R. E., & Raghu, G. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1462704 · Cited by 76
Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E. M., Sand, J. M. B., & Shaker, S. B. (2021) · Respiratory Research · doi:10.1186/s12931-021-01801-0 · Cited by 75
Jia, W., Wang, Z., Gao, C., Wu, J., & Wu, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03603-0 · Cited by 72
Management of Idiopathic Pulmonary Fibrosis
Pleasants, R. A., & Tighe, R. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862497 · Cited by 71
Force, S. D., Kilgo, P., Neujahr, D. C., Pelaez, A., Pickens, A., Fernandez, F. G., Miller, D. L., & Lawrence, C. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.08.055 · Cited by 69
Villavicencio, M. A., Axtell, A. L., Osho, A. A., Astor, T., Roy, N., Melnitchouk, S. I., D’Alessandro, D. A., Tolis, G., Raz, Y., Neuringer, I. P., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.04.060 · Cited by 69
Lung Transplantation in Idiopathic Pulmonary Fibrosis
Hernández, R. L., Pérez, M. A., Mt, L.-C., & Gil, P. U. (2018) · Medical Sciences · doi:10.3390/medsci6030068 · Cited by 62
Serum amyloid P inhibits dermal wound healing
Naik-Mathuria, B. J., Pilling, D., Crawford, J. R., Gay, A. N., Smith, C. W., Gomer, R. H., & Olutoye, O. O. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2008.00366.x · Cited by 61
Hobbs, S., Chung, J. H., Leb, J. S., Kaproth-Joslin, K. A., & Lynch, D. A. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200279 · Cited by 61
The Intersection of GERD, Aspiration, and Lung Transplantation
Patti, M. G., Vela, M. F., Odell, D. D., Richter, J. E., Fisichella, P. M., & Vaezi, M. F. (2016) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1089/lap.2016.0170 · Cited by 59
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1773790 · Cited by 59
Molecular Signatures of Idiopathic Pulmonary Fibrosis
Konigsberg, I. R., Borie, R., Walts, A. D., Cardwell, J., Rojas, M., Metzger, F., Hauck, S. M., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0546oc · Cited by 59
Senanayake, S. J., Harrison, K., Lewis, M. J., McNarry, M. A., & Hudson, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197660 · Cited by 58
Suzuki, Y., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2020) · Respirology · doi:10.1111/resp.13943 · Cited by 57
Chanda, D., Kurundkar, A., Rangarajan, S., Locy, M. L., Bernard, K. F., Sharma, N., Logsdon, N. J., Liu, H., Crossman, D. K., Horowitz, J. C., et al. (2016) · Scientific Reports · doi:10.1038/srep37445 · Cited by 56
Glassberg, M. K. (2019) · PubMed · Cited by 55
Autotaxin Emerges as a Therapeutic Target for Idiopathic Pulmonary Fibrosis
Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0235ed · Cited by 53
Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally
Smith, M. L. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0288-sa · Cited by 50
Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
Machahua, C., Montes‐Worboys, A., Planas‐Cerezales, L., Buendia-Flores, R., Molina‐Molina, M., & Vicens‐Zygmunt, V. (2018) · Respiratory Research · doi:10.1186/s12931-018-0924-7 · Cited by 48
Di Martino, E., Provenzani, A., Vitulo, P., & Polidori, P. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020964451 · Cited by 46 · cited 1×
“gov identifier NCT03955146), a phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial with plans to enroll 340 subjects, is ongoing and will evaluate efficacy and safety of pamrevlumab over 52 weeks.(129,130)”
BackgroundWright, W. A., Crowley, L., Parekh, D., Crawshaw, A., Dosanjh, D. P. S., Nightingale, P., & THICKETT, D. R. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000782 · Cited by 45
Cox, N., Pilling, D., & Gomer, R. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400281 · Cited by 44
Pilling, D., Galvis-Carvajal, E., Karhadkar, T. R., Cox, N., & Gomer, R. H. (2017) · BMC Immunology · doi:10.1186/s12865-017-0214-z · Cited by 44
Etiology and treatment of cough in idiopathic pulmonary fibrosis
Vigeland, C. L., Hughes, A. H., & Horton, M. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.12.016 · Cited by 42
Verma, N., Kumar, P., Mitra, S., Taneja, S., Dhooria, S., Das, A., Duseja, A. K., Dhiman, R. K., & Chawla, Y. K. (2017) · Hepatology Communications · doi:10.1002/hep4.1133 · Cited by 41
Xu, F., Tanabe, N., Vasilescu, D. M., McDonough, J. E., Coxson, H. O., Ikezoe, K., Kinose, D., Ng, K. W., Verleden, S. E., Wuyts, W. A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103325 · Cited by 41
Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis
Bilgili, H., Białas, A. J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081232 · Cited by 40
Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis
Todd, N. W., Atamas, S. P., Luzina, I. G., & Galvin, J. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1067609 · Cited by 39
Zhou, X., Xu, P., Chen, H.-H., Zhao, Y., Shen, J., Jiang, C., Jiang, S., Ni, S.-Z., Xu, B., & Li, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-15239-2 · Cited by 39
Moon, S. W., Kim, S. Y., Chung, M. P., Yoo, H., Jeong, S. H., Kim, D. S., Song, J. W., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-451oc · Cited by 39
Nambiar, S., Clynick, B., Bong, S.-H., King, A. M., Walters, E. H., Goh, N. S. L., Corte, T. J., Trengove, R. D., Tan, D. B. A., & Moodley, Y. P. (2021) · Respiratory Research · doi:10.1186/s12931-021-01682-3 · Cited by 39
Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Balestro, E., Cocconcelli, E., Tinè, M., Biondini, D., Faccioli, E., Saetta, M. P., & Rea, F. (2019) · Medicina · doi:10.3390/medicina55100702 · Cited by 34
Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis
Alhamad, E., Cal, J. G., Alrajhi, N. N., Aharbi, W., Al-Rikabi, A. R. D. A. C., & AlBoukai, A. (2020) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_230_20 · Cited by 34
An updated patent review of autotaxin inhibitors (2017–present)
Tan, Z., Lei, H., Guo, M., Chen, Y., & Zhai, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1867106 · Cited by 34
Kim, G. H. J., Goldin, J. G., Hayes, W., Oh, A. S., Soule, B. P., & Du, S. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211004238 · Cited by 34
Lung Transplantation for Idiopathic Pulmonary Fibrosis
Lamas, D. J., & Lederer, D. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_18 · Cited by 32
Lung transplantation for idiopathic pulmonary fibrosis
Pavec, J. L., Dauriat, G., Gazengel, P., Dolidon, S., Hanna, A., Feuillet, S., Pradère, P., Crutu, A., Florea, V., Boulate, D., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104026 · Cited by 30
Al‐Habeeb, F., Aloufi, N., Traboulsi, H., Liu, X., Nair, P. K., Haston, C. K., Azuelos, I., Huang, S. K., White, E. S., Gallouzi, I., et al. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30380 · Cited by 29
Clubbing in patients with fibrotic interstitial lung diseases
van Manen, M. J. G., Vermeer, L. C., Moor, C. C., Vrijenhoeff, R., Grutters, J. C., Veltkamp, M., & Wijsenbeek, M. S. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.10.021 · Cited by 28
Fishman, J. E., Kim, G. H. J., Kyeong, N. Y., Goldin, J. G., & Glassberg, M. (2019) · PubMed · doi:10.26355/eurrev_201909_18877 · Cited by 27
Feng, H., Zhao, Y., Li, Z., & Kang, J. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620963015 · Cited by 27
Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation
Veit, T., Leuschner, G., Sisic, A., Ceelen, F., Munker, D., Schmitzer, M., Weig, T. G., Michel, S. G., Schneider, C. P., Meiser, B., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15378 · Cited by 23
d’Alessandro, M., Bergantini, L., Torricelli, E., Cameli, P., Lavorini, F., Pieroni, M., Refini, R. M., Sestini, P., & Bargagli, E. (2021) · Cancers · doi:10.3390/cancers13030539 · Cited by 22
Li, D., Liu, Y., & Wang, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233732 · Cited by 21
Yamaguchi, K., Iwamoto, H., Mazur, W., Miura, S., Sakamoto, S., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01410-3 · Cited by 20
Riddell, P., Kleinerová, J., Eaton, D. A., Healy, D. G., Javadpour, H., McCarthy, J. F., Nölke, L., Redmond, K., & Egan, J. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.02413-2019 · Cited by 19
Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
Τzouvelekis, Α., Bouros, E., Oikonomou, A., Ntolios, P., Zacharis, G., Kolios, G. C., & Bouros, D. (2011) · Pulmonary Medicine · doi:10.1155/2011/849035 · Cited by 18
Shall we call them “telomere-mediated”? Renaming the idiopathic after the cause is found
Merck, S. J., & Armanios, M. Y. (2016) · European Respiratory Journal · doi:10.1183/13993003.02115-2016 · Cited by 18
Pastré, J., Barnett, S. D., Ksovreli, I., Taylor, J., Brown, A. W., Shlobin, O. A., Ahmad, K., Khangoora, V. S., Aryal, S., King, C. S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-020-01600-z · Cited by 18
Rahaghi, F., Belperio, J. A., Fitzgerald, J., Gulati, M., Hallowell, R. W., Highland, K. B., Huie, T. J., Kim, G. H. J., Kolb, M. R. J., Lasky, J. A., et al. (2021) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/11795484211006050 · Cited by 18
Schmid, U., Weber, B., Magnusson, M. O., & Freiwald, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106369 · Cited by 15
Taneja, A., Desrivot, J., Diderichsen, P. M., Blanqué, R., Allamassey, L., Fagard, L., Fieuw, A. M., van der Aar, E., & Namour, F. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00755-3 · Cited by 13
Leask, A. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00542-6 · Cited by 13
THICKETT, D. R., Voorham, J., Ryan, R., Jones, R. C. M., Coker, R. K., Wilson, A. M., Yang, S., Ow, M., Raju, P., Chaudhry, I., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034428 · Cited by 13
What parameters can be used to identify early idiopathic pulmonary fibrosis?
Mori, Y., & Kondoh, Y. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.008 · Cited by 13
Nemer, G. M., & Khalil, A. (2019) · Drug Research · doi:10.1055/a-0873-3529 · Cited by 11
Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis
LANCASTER, L. H., Fieuw, A. M., Meulemans, J., Ford, P., & Nathan, S. D. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106227 · Cited by 11
Tuyls, S., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Vos, R., & Verleden, G. M. (2018) · Transplant International · doi:10.1111/tri.13382 · Cited by 10
Eaden, J. A., Barber, C., Renshaw, S. A., Chaudhuri, N., & Bianchi, S. M. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8587 · Cited by 10
Human pentraxin 2 protein treatment for IPF
Τzouvelekis, Α., Tzilas, V., Antoniou, K. M., & Bouros, D. E. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30173-0 · Cited by 8
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Kulkarni, T., & Duncan, S. R. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-00238-7 · Cited by 8
Nemoto, M., Zaizen, Y., Kataoka, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245147 · Cited by 8
Pulmonary fibrosis: Genetic analysis of telomere‐related genes, telomere length measurement‐or both?
Kannengiesser, C., Borie, R., & Renzoni, E. A. (2018) · Respirology · doi:10.1111/resp.13456 · Cited by 7
Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis
Davidsen, J. R., Lund, L. C., Laursen, C. B., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00479-2020 · Cited by 7
SEVERE HEPATOTOXICITY SECONDARY TO NINTEDANIB
Jiménez, M. L., Carrasco, C. H., & Cano, M. D. C. F. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7585/2020 · Cited by 4
Cited by
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Repurposing disulfiram: targeting Zeb1 to attenuate paraquat-induced pulmonary fibrosis in rats
Karimzadeh, F., Daraei, A., Zabihi-Neyshaburi, E., Feizi, F., Ranaee, M., Khafri, S., Esmaeili, Z., & Babazadeh, Z. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10613-1 · Cited by 3
Metadata
- Authors
- Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B.
- Venue
- The Clinical Respiratory Journal
- Publisher
- Wiley
- Published
- 2022-01-10
- Volume
- 16
- Issue
- 2
- Pages
- 84-96
- ISSN
- 1752-6981 (ISSN-L)
- 1752-699X
- OpenAlex
- W4205236090
- Cited by
- 314
- References
- 152
- FWCI
- 37.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.